We will develop novel CD8 + T - cell - inducing adjuvants, focusing on stability, characterisation, pharmaceutical acceptability, and optimal
vaccination strategies (route, prime / boost) with the overall
aim of providing adjuvants and
strategies for effective CD8 + T - cell induction, suitable for human clinical testing.